FDA, Agendia To Determine Scope Of MammaPrint Premarket Regulation
This article was originally published in The Gray Sheet
Executive Summary
Agendia's MammaPrint breast cancer recurrence assay may qualify for a CLIA waiver and require no further premarket regulation, the company says